Earnings Call Summary | Natera(NTRA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Natera(NTRA.US) Q1 2024 Earnings Conference
The following is a summary of the Natera, Inc. (NTRA) Q1 2024 Earnings Call Transcript:
以下是纳泰拉公司（NTRA）2024年第一季度财报电话会议记录的摘要：
Financial Performance:
财务业绩：
Natera achieved cash flow breakeven in Q1 2024, ahead of schedule.
The company reported a revenue increase by 18% from Q4 2023 and 52% from Q1 2023 due to robust volume growth and improved Average Selling Prices (ASPs).
Gross margin stood at a record 57%, a significant increase from 39% in Q1 2023.
The company revised its 2024 revenue guidance to $1.42 billion to $1.45 billion, a 33% growth YoY and expects to maintain gross margins between 53% and 55% for the rest of 2024.
EBITDA, EPS, and cash burn showed significant improvements compared to Q1 last year.
Natera提前在2024年第一季度实现了现金流盈亏平衡。
该公司报告称，由于销量强劲增长和平均销售价格（ASP）的提高，收入较2023年第四季度增长了18％，较2023年第一季度增长了52％。
毛利率达到创纪录的57％，较2023年第一季度的39％大幅增长。
该公司将其2024年的收入预期修订为14.2亿美元至14.5亿美元，同比增长33％，并预计将在2024年剩余时间内将毛利率维持在53％至55％之间。
与去年第一季度相比，息税折旧摊销前利润、每股收益和现金消耗均有显著改善。
Business Progress:
业务进展：
Natera introduced a new RhD prenatal testing product as a key differentiator, and Renasight's usage has been encouraged due to revised KDIGO guidelines.
Prospera was demonstrated to detect kidney transplant rejections earlier in the Proactive trial.
Signatera, Natera's cancer test, made substantial contributions to Q1 growth and showed efficacy in both gynecological oncology and breast cancer.
Natera is planning future product launches, beginning with the RhD test, and expects to see positive impacts from biomarker-related reimbursement in 2025.
Significant volume growth was seen, specifically in the women's health sector, and the firm sees potential for continued growth in this area.
Natera推出了一款新的RhD产前检查产品作为关键差异化因素，由于修订了KDIGO指南，因此鼓励使用Renasight。
Prospera在早些时候的Procative试验中被证明可以检测出肾脏移植排斥反应。
Natera的癌症测试Signatera对第一季度的增长做出了重大贡献，并在妇科肿瘤学和乳腺癌中均显示出疗效。
Natera正计划未来的产品发布，从RhD测试开始，并预计在2025年生物标志物相关报销将产生积极影响。
销量显著增长，特别是在女性健康领域，该公司认为该领域有持续增长的潜力。
More details: Natera IR
更多详情： 纳泰拉红外线
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。